Cantargia receives an Intention to Grant notice in Europe for its CAN04 product candidate
Cantargia AB (“Cantargia”) today announced that the company has received an Intention to Grant notice from the European Patent Office (“EPO”) for its patent application for the CAN04 product candidate. In essence, this means that the EPO intends to approve the company’s application.
The patent application, with application number 15714603.6, for which the EPO has issued an Intention to Grant notice, refers to the company’s CAN04 product candidate. The patent protects Cantargia’s CAN04 product candidate as a substance as well as its specific use for treatment of various forms of cancer. The notice of the Intention to Grant means that the EPO intends to approve the company’s patent application but that a number of administrative steps remain before a final notice of approval can be issued. The patent, when granted, provides protection of CAN04 in Europe until 2035.
In addition to Europe, Cantargia has submitted patent applications for CAN04 in several other territories, including the United States, Japan and China.
“The granting of a patent for our CAN04 product candidate is an important part of our efforts to build value in our portfolio”, Göran Forsberg, CEO of Cantargia, says. “We are very pleased that the examination of our application was completed quickly and that we have now taken a big step towards obtaining a patent in this large and important market”.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 5 April 2017, at 2.15 pm
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.
Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.